TY - JOUR T1 - Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal JO - PharmacoEconomics UR - https://eprints.whiterose.ac.uk/id/eprint/116243 UR - https://doi.org/10.1007/s40273-016-0386-z PY - 2016/07/01 AU - Squires H AU - Stevenson M AU - Simpson E AU - Harvey R AU - Stevens J ED - DO - DOI: 10.1007/s40273-016-0386-z PB - Springer Verlag VL - 34 IS - 7 SP - 673 EP - 680 Y2 - 2025/04/11 ER -